CN103877569B - A kind of compound lysostaphin enzyme disinfectant - Google Patents
A kind of compound lysostaphin enzyme disinfectant Download PDFInfo
- Publication number
- CN103877569B CN103877569B CN201410148968.9A CN201410148968A CN103877569B CN 103877569 B CN103877569 B CN 103877569B CN 201410148968 A CN201410148968 A CN 201410148968A CN 103877569 B CN103877569 B CN 103877569B
- Authority
- CN
- China
- Prior art keywords
- parts
- disinfectant
- lysostaphin enzyme
- enzyme disinfectant
- compound lysostaphin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000645 desinfectant Substances 0.000 title claims abstract description 25
- 108090000988 Lysostaphin Proteins 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 title claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 18
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims abstract description 18
- 102000016943 Muramidase Human genes 0.000 claims abstract description 13
- 108010014251 Muramidase Proteins 0.000 claims abstract description 13
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 13
- 241000191940 Staphylococcus Species 0.000 claims abstract description 13
- 229960000274 lysozyme Drugs 0.000 claims abstract description 13
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 13
- 239000004325 lysozyme Substances 0.000 claims abstract description 13
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 102000004317 Lyases Human genes 0.000 claims abstract description 9
- 108090000856 Lyases Proteins 0.000 claims abstract description 9
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 9
- 239000012153 distilled water Substances 0.000 claims abstract description 9
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 9
- 229910000160 potassium phosphate Inorganic materials 0.000 claims abstract description 9
- 235000011009 potassium phosphates Nutrition 0.000 claims abstract description 9
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 210000004877 mucosa Anatomy 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001537924 Tetracoccus <angiosperm> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003559 chemosterilizing effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention discloses a kind of compound lysostaphin enzyme disinfectant, and it comprises the component of following parts by weight: staphylococcus lysozyme 20 ~ 40 parts, Polyethylene Glycol 2 ~ 8 parts, Mentholum 0.2 ~ 0.5 part, maltose 10 ~ 15 parts, hyaluronate sodium 5 ~ 10 parts, 0.5 ~ 2 part, sodium chloride, lyase bacterium 50 ~ 60 parts, potassium phosphate 7 ~ 10 parts and distilled water 30 ~ 40 parts.The invention allows for the preparation method of above-mentioned compound lysostaphin enzyme disinfectant.Compound lysostaphin enzyme disinfectant of the present invention can not produce skin and mucosa to stimulate, and can not produce toxic and side effects, and thoroughly degrade by metabolism to body, and not residual.
Description
Technical field
The present invention relates to a kind of biological preparation, relate to a kind of compound lysostaphin enzyme disinfectant particularly.
Background technology
The disinfectant of current use mostly is chemosterilant, as the disinfectant of coagulated protein class, and its object mainly through making albuminous degeneration reach sterilization; Soluble protein class disinfectant, it reaches kill activity mainly through making biosolubilization, as sodium hydroxide or Calx etc.; The disinfectant of oxidation protein class, its strong oxidation mainly through oxidant kills pathogen, comprises bleaching powder, peracetic acid etc.; Cation surface-active disinfectant, mainly comprises some quaternary ammonium salts, and it is coagulated protein when high concentration, and low concentration is the metabolism of anti-bacteria; Also have some as the disinfectant of formalin, glutaraldehyde or ethylene oxide.But the disinfectant of above-mentioned chemical classes not only can cause certain pollution to environment, and can be with in clinical middle sterilization and serve toxic and side effects, as to skin and mucous membrane irritation, to blood flow wound and the stimulation of blood stains wound surface etc.
Staphylococcus lysozyme is a kind of bacteriolysin of gram positive bacteria.Staphylococcus lysozyme can cut off the Gly-Gly key in Peptidoglycan, and another kind of enzyme can cut off the key between-acetylmuramic acid and N-Acetyl-D-glucosamine in composite lysostaphin, thus make bactericidal activity stronger, reach and dissolve and kill the object of antibacterial, and the generation of bacterial drug resistance can be avoided.The mechanism of action of staphylococcus lysozyme is different from general antibiotic, antibiotic effect is only bacteria growing inhibiting, this enzyme is then cracking antibacterial and kills antibacterial, and has stronger sterilizing ability equally to the staphylococcus aureus of methicillin-resistance (MRSA).
Summary of the invention
Goal of the invention: be solve in prior art the technical problem existed, the present invention propose a kind of good stability, fungicidal spectrum wide, non-stimulated to skin mucosa, have no side effect and safe and reliable compound lysostaphin enzyme disinfectant.
Technology contents: for realizing above-mentioned technical purpose, the present invention proposes a kind of compound lysostaphin enzyme disinfectant, and it comprises the component of following parts by weight: staphylococcus lysozyme 20 ~ 40 parts, Polyethylene Glycol 2 ~ 8 parts, Mentholum 0.2 ~ 0.5 part, maltose 10 ~ 15 parts, hyaluronate sodium 5 ~ 10 parts, 0.5 ~ 2 part, sodium chloride, lyase bacterium 50 ~ 60 parts, potassium phosphate 7 ~ 10 parts and distilled water 30 ~ 40 parts.
Preferably, described compound lysostaphin enzyme disinfectant comprises the component of following parts by weight: staphylococcus lysozyme 30 parts, Polyethylene Glycol 5 parts, Mentholum 0.3 part, maltose 12 parts, hyaluronate sodium 8 parts, 1 part, sodium chloride, lyase bacterium 55 parts, potassium phosphate 8 parts and distilled water 35 parts.
The invention allows for the preparation method of above-mentioned compound lysostaphin enzyme disinfectant, it is characterized in that, comprise the steps: aseptically, the staphylococcus lysozyme of formula ratio, Polyethylene Glycol, Mentholum, maltose, hyaluronate sodium, sodium chloride, lyase bacterium and potassium phosphate are joined in the distilled water of formula ratio, abundant mix homogeneously and get final product.
Beneficial effect: compared with prior art, compound lysostaphin enzyme disinfectant of the present invention can not produce skin and mucosa to stimulate, and can not produce toxic and side effects, and thoroughly degrade by metabolism to body, and not residual.
Detailed description of the invention
The preparation of embodiment 1 ~ 5 compound lysostaphin enzyme disinfectant.
According to the formulated compound lysostaphin enzyme disinfectant in table 1.Its preparation method is aseptically, joins in the distilled water of formula ratio by the staphylococcus lysozyme of formula ratio, Polyethylene Glycol, Mentholum, maltose, hyaluronate sodium, sodium chloride, lyase bacterium and potassium phosphate, abundant mix homogeneously and get final product.
Table 1 compound lysostaphin enzyme disinfectant formula (parts by weight)
| Component | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 |
| Staphylococcus lysozyme | 30 | 20 | 40 | 35 | 25 |
| Polyethylene Glycol | 5 | 8 | 2 | 6 | 7 |
| Mentholum | 0.3 | 0.2 | 0.5 | 0.3 | 0.4 |
| Maltose | 12 | 15 | 10 | 13 | 12 |
| Hyaluronate sodium | 8 | 5 | 10 | 9 | 7 |
| Sodium chloride | 1 | 2 | 0.5 | 1 | 1.5 |
| Lyase bacterium | 55 | 50 | 60 | 58 | 54 |
| Potassium phosphate | 8 | 10 | 7 | 9 | 8 |
| Distilled water | 35 | 30 | 40 | 35 | 37 |
Result shows, compound lysostaphin enzyme disinfectant prepared by the present invention to gram positive bacteria, as staphylococcus aureus, staphylococcus epidermidis, Diplococcus pneumoniae, D group enterococcus, tetracoccus, Listeria monocytogenes, streptococcus and stomach Helicobacter pylori all have obvious inhibitory or killing effect.
Meanwhile, experiment shows that staphylococcus lysozyme is to drug resistance monarch, as methicillin-resistant staphylococcus aureus, drug resistance Diplococcus pneumoniae, addicted to the effect of the narrow food sporangium of Fructus Hordei Germinatus more due to conventional antibiotic.
Claims (3)
1. a compound lysostaphin enzyme disinfectant, it is characterized in that, it comprises the component of following parts by weight: staphylococcus lysozyme 20 ~ 40 parts, Polyethylene Glycol 2 ~ 8 parts, Mentholum 0.2 ~ 0.5 part, maltose 10 ~ 15 parts, hyaluronate sodium 5 ~ 10 parts, 0.5 ~ 2 part, sodium chloride, lyase bacterium 50 ~ 60 parts, potassium phosphate 7 ~ 10 parts and distilled water 30 ~ 40 parts.
2. a compound lysostaphin enzyme disinfectant, it is characterized in that, it comprises the component of following parts by weight: staphylococcus lysozyme 30 parts, Polyethylene Glycol 5 parts, Mentholum 0.3 part, maltose 12 parts, hyaluronate sodium 8 parts, 1 part, sodium chloride, lyase bacterium 55 parts, potassium phosphate 8 parts and distilled water 35 parts.
3. the preparation method of the compound lysostaphin enzyme disinfectant described in claim 1 or 2, it is characterized in that, comprise the steps: aseptically, the staphylococcus lysozyme of formula ratio, Polyethylene Glycol, Mentholum, maltose, hyaluronate sodium, sodium chloride, lyase bacterium and potassium phosphate are joined in the distilled water of formula ratio, abundant mix homogeneously and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410148968.9A CN103877569B (en) | 2014-04-14 | 2014-04-14 | A kind of compound lysostaphin enzyme disinfectant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410148968.9A CN103877569B (en) | 2014-04-14 | 2014-04-14 | A kind of compound lysostaphin enzyme disinfectant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103877569A CN103877569A (en) | 2014-06-25 |
| CN103877569B true CN103877569B (en) | 2016-01-06 |
Family
ID=50946903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410148968.9A Expired - Fee Related CN103877569B (en) | 2014-04-14 | 2014-04-14 | A kind of compound lysostaphin enzyme disinfectant |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103877569B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524557A (en) * | 2014-12-16 | 2015-04-22 | 杨陈 | Lysostaphin compound disinfection gel |
| CN105169378A (en) * | 2015-08-12 | 2015-12-23 | 江苏绿科生物技术有限公司 | Preparation method of complex lysostaphin disinfectant |
| CN104996467A (en) * | 2015-08-12 | 2015-10-28 | 江苏绿科生物技术有限公司 | Complex lysostaphin disinfectant |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327742A (en) * | 2000-06-08 | 2001-12-26 | 上海高科生物工程有限公司 | Compound lysostaphin enzyme disinfectant |
| CN1327741A (en) * | 2000-06-08 | 2001-12-26 | 上海高科生物工程有限公司 | Compound lysostaphin enzyme disinfectant |
| CN1360949A (en) * | 2000-12-28 | 2002-07-31 | 上海高科生物工程有限公司 | Bactericidal gauze with lysostaphin complex enzyme |
| CN1415209A (en) * | 2002-11-21 | 2003-05-07 | 上海高科生物工程有限公司 | Method for preparing the bactericide and the cleansing facial milk] |
| CN102639097A (en) * | 2011-03-21 | 2012-08-15 | 博任达生化科技（上海）有限公司 | Reverse thermo-sensitivity reversible aquogel composite |
-
2014
- 2014-04-14 CN CN201410148968.9A patent/CN103877569B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327742A (en) * | 2000-06-08 | 2001-12-26 | 上海高科生物工程有限公司 | Compound lysostaphin enzyme disinfectant |
| CN1327741A (en) * | 2000-06-08 | 2001-12-26 | 上海高科生物工程有限公司 | Compound lysostaphin enzyme disinfectant |
| CN1360949A (en) * | 2000-12-28 | 2002-07-31 | 上海高科生物工程有限公司 | Bactericidal gauze with lysostaphin complex enzyme |
| CN1415209A (en) * | 2002-11-21 | 2003-05-07 | 上海高科生物工程有限公司 | Method for preparing the bactericide and the cleansing facial milk] |
| CN102639097A (en) * | 2011-03-21 | 2012-08-15 | 博任达生化科技（上海）有限公司 | Reverse thermo-sensitivity reversible aquogel composite |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103877569A (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019202045B2 (en) | Treatment of Microbial Infections | |
| CN103877569B (en) | A kind of compound lysostaphin enzyme disinfectant | |
| EP2987408A1 (en) | Iodophor composition with improved stability in the presence of organic material | |
| KR101913718B1 (en) | Compositions for sterilization and disinfection comprising octenidine and benzalconium chloride | |
| CN101766186A (en) | Composition capable of slowly-releasing chlorine dioxide and application thereof | |
| EP2965624A1 (en) | Concentrate for a disinfectant, disinfectant and process for disinfecting a surface | |
| CN103766402A (en) | Disinfectant and preparation method thereof | |
| CN103012237B (en) | Amino-acid dual-chain quaternary-amino carboxylate, preparation method and application in microbicides thereof | |
| CN107836462B (en) | Pseudomonas aeruginosa disinfectant and sterilization method suitable for production of barreled drinking water | |
| CN107568222A (en) | A kind of compound glutaraldehyde Deciquam persistent disinfectant | |
| KR20210038465A (en) | Composite for antibacterial and deodorant agent using ionized minerals and persimmon leaf extract and other natural materials | |
| CN104524559A (en) | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof | |
| KR101835098B1 (en) | Hand wash compositions using natural extracts | |
| CN111658560A (en) | Powerful private part killing lotion and preparation method thereof | |
| JP6310745B2 (en) | Bactericidal composition | |
| CN105169378A (en) | Preparation method of complex lysostaphin disinfectant | |
| CN104524558A (en) | Enzyme compounded preparation and preparation method thereof | |
| CN104496954B (en) | Preparation method of functionalized nano-selenium | |
| CN103238595B (en) | Special concentrated type glutaraldehyde disinfectant for endoscopes and preparation method of special concentrated type glutaraldehyde disinfectant | |
| CN111165493A (en) | Mixed liquid deodorizing disinfectant and preparation method thereof | |
| KR101397225B1 (en) | Method for manufacturing spray composition and spray composition therefor | |
| CN104663658A (en) | Sterilizing agent and preparation method thereof | |
| KR20110061311A (en) | Antibiotic composition using low molecular weight silver-alginate and manufacturing method thereof and biotic pesticide using the same | |
| Ramey et al. | Commercial and homemade extremely dilute hypochlorous acid solutions are bactericidal against Staphylococcus aureus and Escherichia coli in vitro | |
| CN105028473A (en) | Domestic compound multipurpose disinfection powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LI ZHICHEN Free format text: FORMER OWNER: SONG WEI Effective date: 20150827 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Zhichen Inventor after: Song Wei Inventor before: Song Wei |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SONG WEI TO: LI ZHICHEN SONG WEI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150827 Address after: Qixia Xiaozhuang Village Center District of Nanjing City, Jiangsu province 210038 No. 130 Jinling Institute of Technology campus shogunate Applicant after: Li Zhichen Address before: 210038, Jiangsu, Nanjing province Qixia District swallow rocky street, Ba Doo Shan, No. 14 Applicant before: Song Wei |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160106 Termination date: 20160414 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |